Your browser doesn't support javascript.
loading
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.
Bunyasi, E W; Luabeya, A K K; Tameris, M; Geldenhuys, H; Mulenga, H; Landry, B S; Scriba, T J; Schmidt, B-M; Hanekom, W A; Mahomed, H; McShane, H; Hatherill, M.
  • Bunyasi EW; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Luabeya AKK; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Tameris M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Geldenhuys H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mulenga H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Landry BS; Aeras, Rockville, Maryland, USA.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Schmidt BM; Department of Social and Behavioral Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town.
  • Hanekom WA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mahomed H; Department of Health, Western Cape and Division of Community Health, Stellenbosch University, Stellenbosch, South Africa.
  • McShane H; Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Int J Tuberc Lung Dis ; 21(7): 778-783, 2017 07 01.
Article en En | MEDLINE | ID: mdl-28633702
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Vacunas contra la Tuberculosis / Isoniazida / Antituberculosos Tipo de estudio: Clinical_trials / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male País como asunto: Africa Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Vacunas contra la Tuberculosis / Isoniazida / Antituberculosos Tipo de estudio: Clinical_trials / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male País como asunto: Africa Idioma: En Año: 2017 Tipo del documento: Article